9 Meters Biopharma, Inc. (NMTRQ) Stock Analysis

9 Meters Biopharma, Inc. (NMTRQ) Healthcare & Pipeline Overview

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical firm specializing in innovative therapies for rare digestive diseases, with a focus on unmet medical needs in gastrointestinal disorders, particularly through its lead candidate, Vurolenatide.

What Is the Investment Thesis for NMTRQ?

9 Meters Biopharma, Inc. operates in a niche segment of the biotechnology industry focused on rare digestive diseases, which presents unique growth opportunities. The company's lead candidate, Vurolenatide, is in Phase 3 trials, potentially positioning it for market entry should it receive regulatory approval. The market for treatments addressing short bowel syndrome and related gastrointestinal disorders is significant, with increasing awareness and demand for effective therapies. However, the company faces substantial risks, including its recent bankruptcy filing, which complicates its operational viability and future funding prospects. The outcome of ongoing clinical trials and the ability to secure partnerships or funding will be critical in determining the company’s future trajectory.

Based on FMP financials and quantitative analysis

NMTRQ Key Highlights

Market Cap: $0.00B due to bankruptcy proceedings.

• ROE: -375.6%, indicating significant financial distress.
• Free Cash Flow: -$0.02B, reflecting ongoing operational challenges.
• Beta: 9.33, suggesting high volatility in stock performance.
• Dividend Yield: None, as the company does not currently distribute dividends.

Who Are NMTRQ's Competitors?

NMTRQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NMTRQ's Key Strengths?

Innovative pipeline with multiple drug candidates targeting rare diseases.

• Strong focus on unmet medical needs in gastrointestinal health.
• Established partnerships with other biopharmaceutical firms.

What Are NMTRQ's Weaknesses?

Recent bankruptcy filing raises concerns about financial stability.

• Limited operational scale with only 10 employees.
• High volatility in stock performance due to market conditions.

What Could Drive NMTRQ Stock Higher?

NMTRQ catalyst: Phase 3 clinical trials for Vurolenatide, which could lead to potential market entry if successful.

• Potential licensing agreements that could provide additional funding or resources for development.
• Continued research and development efforts on NM-136 and NM-102, targeting obesity and autoimmune diseases.

What Are the Key Risks for NMTRQ?

Financial instability due to the recent bankruptcy filing, impacting operations and funding.

• Regulatory hurdles that could delay or prevent approval of drug candidates.
• High competition in the biotechnology sector, which may hinder market penetration.

What Are the Growth Opportunities for NMTRQ?

• Growth opportunity 1: The market for short bowel syndrome treatments is projected to grow significantly, driven by increasing diagnosis rates and a growing patient population. As awareness of this debilitating condition rises, the demand for effective therapies like Vurolenatide could expand, potentially capturing a significant share of the market, which is estimated to exceed $1 billion by 2028.
• Growth opportunity 2: The obesity treatment market is experiencing rapid growth, with increasing prevalence rates globally. NM-136, the company's humanized monoclonal antibody, targets obesity and related metabolic disorders, which are becoming critical public health issues.
• Growth opportunity 3: The development of NM-102, aimed at preventing antigen entry into systemic circulation, addresses a significant unmet need in various autoimmune and inflammatory conditions.
• Growth opportunity 4: NM-003, targeting acute graft versus host disease, represents an opportunity in the oncology and transplant sectors, where there is a high demand for effective preventative therapies. The market for graft versus host disease treatments is expected to grow as more patients undergo stem cell transplants, potentially reaching $1 billion by 2026.
• Growth opportunity 5: The partnership with Amunix and other licensing agreements could provide additional revenue streams and enhance the company's research capabilities. Collaborations in the biotechnology space are increasingly common, and successful partnerships can lead to accelerated development timelines and shared financial burdens, positioning 9 Meters Biopharma for future growth.

What Threats Does NMTRQ Face?

• Intense competition from other biotechnology firms.
• Regulatory challenges in drug approval processes.
• Market volatility impacting investor confidence and funding availability.

What Are NMTRQ's Competitive Advantages?

• Specialization in rare diseases provides a unique market position with less competition.
• Strong pipeline of innovative therapies targeting unmet medical needs.
• Established partnerships with reputable organizations enhance credibility and research capabilities.
• Intellectual property protections for proprietary drug candidates create barriers to entry.
• Clinical-stage advancements in drug development increase potential for future revenue streams.

What Does NMTRQ Do?

Founded with the mission to address significant gaps in treatment for rare digestive diseases, 9 Meters Biopharma, Inc. has positioned itself as a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from gastrointestinal disorders. Headquartered in Raleigh, North Carolina, the company has focused its efforts on creating effective treatments for conditions that currently lack adequate therapeutic options. Its primary product candidate, Vurolenatide, is a long-acting injectable glucagon-like peptide-1 that has advanced to Phase 3 clinical trials for the management of short bowel syndrome, a debilitating condition that significantly impacts patients' quality of life. In addition to Vurolenatide, 9 Meters Biopharma has developed a diverse pipeline of products, including NM-136, a humanized monoclonal antibody targeting obesity and related conditions; NM-102, a small molecule peptide designed to prevent antigen entry into systemic circulation; and NM-003, a proprietary glucagon-like peptide-2 receptor agonist aimed at preventing acute graft versus host disease. The company has also partnered on Larazotide, an 8-amino acid peptide that is currently in Phase 2 clinical trials for multi-system inflammatory syndrome. Despite its innovative pipeline and strategic licensing agreements with entities such as Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS, 9 Meters Biopharma faced significant financial challenges, leading to a voluntary petition for liquidation under Chapter 7 of the U.S. Bankruptcy Code on July 17, 2023.

What Products and Services Does NMTRQ Offer?

• Develop therapies for rare digestive diseases and gastrointestinal disorders.
• Focus on innovative treatments for conditions with unmet medical needs.
• Conduct clinical trials to evaluate the efficacy and safety of its drug candidates.
• Engage in partnerships and licensing agreements to enhance its research capabilities.
• Target specific conditions such as short bowel syndrome, obesity, and acute graft versus host disease.
• Utilize advanced biopharmaceutical technologies to create long-acting injectable therapies.

How Does NMTRQ Make Money?

• Generate revenue through the development and commercialization of pharmaceutical products.
• Engage in licensing agreements with other biopharmaceutical companies to expand product offerings.
• Conduct clinical trials funded by partnerships and grants to support research and development.
• Focus on niche markets with high unmet medical needs to capture market share.
• Leverage intellectual property and proprietary technologies to create competitive advantages.

What Industry Does NMTRQ Operate In?

The biotechnology industry is characterized by rapid innovation and significant investment in research and development. With a growing focus on personalized medicine and targeted therapies, companies like 9 Meters Biopharma are positioned within a market that is expected to expand significantly. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, driven by advancements in drug development and increasing prevalence of chronic diseases. However, the competitive landscape is intense, with numerous players vying for market share in therapeutic areas that address unmet medical needs.

Who Are NMTRQ's Key Customers?

• Patients suffering from rare digestive diseases and gastrointestinal disorders.
• Healthcare providers seeking effective treatment options for their patients.
• Pharmaceutical partners interested in licensing or collaborating on drug development.
• Investors and stakeholders looking for innovative biopharmaceutical opportunities.
• Regulatory bodies involved in the approval and oversight of new therapies.

Company Profile

9 Meters Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Raleigh, US. The company is led by CEO Peter H. R. Green. NMTRQ has traded publicly since 2016.

NMTRQ Financials

NMTRQ Latest News

No recent news available for NMTRQ.

NMTRQ Analyst Consensus

NMTRQ MoonshotScore

NMTRQ Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources